Although Jakafi has been approved for patients with higher-risk myelofibrosis, those with lower-risk disease may also benefit ...

Truist Securities has downgraded Incyte Corporation (NASDAQ:INCY), noting Jakafi’s (ruxolitinib) patent loss approaching in ...

Vonjo was also shown to improve overall survival in patients with myelofibrosis treated with Vonjo in the real-world setting.

Ruxolitinib can cause cytopenia, the most prominent adverse event (AE). There are rates of anemia and thrombocytopenia in ...

The phase 3 Shorespan-007 trial will compare bomedemstat with hydroxyurea in patients with treatment-naive essential ...

GSK has reported positive results from its phase II trial for an mRNA seasonal influenza vaccine candidate, showing strong immune responses again ...

Inflammation and genetic mutations can drive cardiovascular complications in patients with myeloproliferative neoplasms, which include disorders such as polycythemia vera, essential thrombocythemia, ...

Using NGS in prognostic assessments enhances myelofibrosis prognosis and survival estimates, representing a step toward personalized medicine in myelofibrosis.

As recently as 2016, Swedish Orphan Biovitrum, or Sobi, was largely a specialty pharmaceutical firm in-licensing rights to market drugs in Europe. Since then, the successful launches of hemophilia ...

Meet Kid Captain Mya Gilchrist.After experiencing balance issues when she was 18 months old, Mya Gilchrist was diagnosed with ...

Imetelstat sodium is under clinical development by Geron and currently in Phase III for Post-Polycythemia Vera Myelofibrosis (PPV-MF). According to GlobalData, Phase III drugs for Post-Polycythemia ...